Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload

Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron concentrations (LIC), although some patients may require intensive chelation for a limited duration. HYPERION, an open-label single-arm prospective phase 2 study, evaluated combination DFX-deferoxamine (DFO) in patient...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood
Huvudupphovsmän: Aydinok, Yesim, Kattamis, Antonis, Cappellini, M. Domenica, El-Beshlawy, Amal, Origa, Raffaella, Elalfy, Mohsen, Kilinç, Yurdanur, Perrotta, Silverio, Karakas, Zeynep, Viprakasit, Vip, Habr, Dany, Constantinovici, Niculae, Shen, Junwu, Porter, John B.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2015
Ämnen:
Clinical Trials and Observations
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4490296/
https://ncbi.nlm.nih.gov/pubmed/25934475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-07-586677
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk